Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.30 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974652 | 0.84 | TRPV4 (0.58) | TRPV4CYP11B1CYP11B2EGLN2TTR | |
| SCHEMBL16596444 | 0.84 | TTR (0.36) | TRPV4EPAS1TTRALB | |
| SCHEMBL425826 | 0.78 | TRPV4 (0.46) | TRPV4CYP11B1CYP11B2TTRALB | |
| SCHEMBL27219870 | 0.78 | TRPV4 (0.46) | TRPV4EPAS1TTRALB | |
| SCHEMBL18305809 | 0.75 | TRPV4 (0.43) | TRPV4EPAS1CYP11B1CYP11B2 | |
| SCHEMBL31113834 | 0.75 | TRPV4 (0.43) | TRPV4 | |
| SCHEMBL1317673 | 0.75 | TRPV4 (0.43) | TRPV4CYP11B1CYP11B2TTRALB | |
| SCHEMBL13868306 | 0.75 | TRPV4 (0.43) | TRPV4 | |
| SCHEMBL15674088 | 0.75 | TRPV4 (0.43) | TRPV4CYP11B1CYP11B2 | |
| SCHEMBL27219876 | 0.75 | TRPV4 (0.43) | TRPV4EPAS1CYP11B1CYP11B2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023155886-A1 | PYRAZOLOPYRIDINE COMPOUNDS AS TAM INHIBITORS | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2023-08-24 | — | — | WO | disclosed |
| CN-116437918-A | Pyrazolopyridine compounds as TAM inhibitors | 上海德琪医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023051464-A1 | PYRAZOLOPYRIDINE COMPOUNDS AS TAM INHIBITORS | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2023-04-06 | — | — | WO | disclosed |
| US-8940778-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8642776-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130030189-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8299243-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2246333-B1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2012-10-24 | — | — | EP | disclosed |
| CN-102417487-A | Indazole, benzisoxazole and benzisothiazole kinase inhibitors | ABBOTT LAB | 2012-04-18 | — | — | CN | disclosed |
| EP-1638941-B1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LAB (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-7598283-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBVIE INC. | 2008-03-27 | — | — | US | disclosed |
| US-7297709-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-11-20 | — | — | US | disclosed |
| CN-1826324-A | Indazole, benzisoxazole and benzisothiazole kinase inhibitors | ABBOTT LAB (US) | 2006-08-30 | — | — | CN | disclosed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABBOTT LABORATORIES | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245015-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | TRPV4 1860/4885EPAS1 2273/4885CYP11B1 1164/4885 |
| US-20080076767-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | TRPV4 1860/4885EPAS1 2273/4885CYP11B1 1164/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | TRPV4 1860/4885EPAS1 2273/4885CYP11B1 1164/4885 |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABL1, MAP3K19, MAP3K1 | TRPV4 2605/4885EPAS1 1628/4885CYP11B1 618/4885 |
| US-20090286784-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | TRPV4 1860/4885EPAS1 2273/4885CYP11B1 1164/4885 |
| US-20130030189-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABL1, BLK, BTK | TRPV4 1860/4885EPAS1 2273/4885CYP11B1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.